Trial intelligence / Profile preview

iNeo-Vac-R01 in advanced digestive system neoplasms

NCT06026800Phase 1Recruiting

Sponsor
Sir Run-Run Shaw Hospital
Start
Sep 2023
Primary completion
Aug 2027
Modality
Vaccines & Immunotherapeutics, mRNA Therapeutics
Countries
1
01

Overview

Phase 1, open-label, single-arm trial of iNeo-Vac-R01 in digestive system neoplasms, sponsored by Sir Run-Run Shaw Hospital. Primary endpoint: Number of Participants with Adverse Events. Started Sep 2023; status: recruiting.

02

Drugs

iNeo-Vac-R01
03

Conditions

digestive system neoplasms

Beyond the preview

Go deeper on NCT06026800.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT06026800.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call